The U.S. consumer prices report released this week revealed a less-than-expected increase in December, signaling a potential ...

Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $268.94 which represents a slight increase of $1.84 or 0.69% from the prior close of $267.1. The stock opened at $269.33 and touched a low ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Amgen is expected to post earnings ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $270.19 which represents a slight increase of $7.96 or 3.04% from the prior close of $262.23. The stock opened at $262.11 and touched a ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00.Stay ...

These stocks are all trading near their 52-week lows, and could be attractive options to consider. They all possess promising ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...